Celyad Oncology SA
CLYYF
$0.20
-$0.21-51.22%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.33% | -2.63% | 193.91% | 199.05% | -68.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.33% | -2.63% | 193.91% | 199.05% | -68.62% |
| Cost of Revenue | -6.25% | -14.29% | -88.15% | -88.24% | -79.92% |
| Gross Profit | 25.93% | 18.52% | 406.18% | 416.11% | -- |
| SG&A Expenses | 1.93% | -6.30% | -44.04% | -42.91% | -53.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 44.78% | 49.20% | -215.07% | -222.13% | 81.50% |
| Total Operating Expenses | 24.85% | 14.77% | -38.82% | -37.58% | -36.96% |
| Operating Income | -24.93% | -14.85% | 41.67% | 40.50% | 36.67% |
| Income Before Tax | -27.30% | -17.03% | 42.31% | 41.15% | 19.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -27.30% | -17.03% | 41.53% | 40.36% | 19.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.30% | -17.03% | 41.53% | 40.36% | 19.52% |
| EBIT | -24.93% | -14.85% | 41.67% | 40.50% | 36.67% |
| EBITDA | -27.42% | -17.14% | 42.23% | 42.07% | 36.10% |
| EPS Basic | -33.42% | -17.04% | 59.23% | 58.45% | 59.24% |
| Normalized Basic EPS | -34.04% | -17.27% | 59.86% | 58.87% | 68.41% |
| EPS Diluted | -33.42% | -17.04% | 59.23% | 58.45% | 59.24% |
| Normalized Diluted EPS | -34.04% | -17.27% | 59.86% | 58.87% | 68.41% |
| Average Basic Shares Outstanding | -4.73% | 0.00% | 43.60% | 43.60% | 97.66% |
| Average Diluted Shares Outstanding | -4.73% | 0.00% | 43.60% | 43.60% | 97.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |